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Chloroquine Dosing Recommendations for 
Pediatric COVID-19 Supported by Modeling 
and Simulation
Laurens F. M. Verscheijden1, Tjitske M. van der Zanden1,2,3, Lianne P. M. van Bussel1,  
Marika de Hoop-Sommen2,4, Frans G. M. Russel1, Trevor N. Johnson5 and Saskia N. de Wildt1,2,6,*
As chloroquine (CHQ) is part of the Dutch Centre for Infectious Disease Control coronavirus disease 2019 (COVID-19)  
experimental treatment guideline, pediatric dosing guidelines are needed. Recent pediatric data suggest that  
existing World Health Organization (WHO) dosing guidelines for children with malaria are suboptimal. The aim  
of our study was to establish best-evidence to inform pediatric CHQ doses for children infected with COVID-19.  
A previously developed physiologically-based pharmacokinetic (PBPK) model for CHQ was used to simulate exposure 
in adults and children and verified against published pharmacokinetic data. The COVID-19 recommended adult 
dosage regimen of 44 mg/kg total was tested in adults and children to evaluate the extent of variation in exposure. 
Based on differences in area under the concentration-time curve from zero to 70 hours (AUC0–70h) the optimal CHQ 
dose was determined in children of different ages compared with adults. Revised doses were re-introduced into the 
model to verify that overall CHQ exposure in each age band was within 5% of the predicted adult value. Simulations 
showed differences in drug exposure in children of different ages and adults when the same body-weight based dose 
is given. As such, we propose the following total cumulative doses: 35 mg/kg (CHQ base) for children 0–1 month, 
47 mg/kg for 1–6 months, 55 mg/kg for 6 months–12 years, and 44 mg/kg for adolescents and adults, not to 
exceed 3,300 mg in any patient. Our study supports age-adjusted CHQ dosing in children with COVID-19 in order 
to avoid suboptimal or toxic doses. The knowledge-driven, model-informed dose selection paradigm can serve as a 
science-based alternative to recommend pediatric dosing when pediatric clinical trial data is absent.
With coronavirus disease 2019 (COVID-19) spreading rapidly 
across the globe, effective drug treatment is desperately needed. 
Based on Chinese population data, <  1% of the infected cases 
were children below the age of 10 years and clinical symptoms in 
these patients were milder compared with adults.1 However, it is 
unknown how such numbers will evolve when a higher percentage 
of the entire world population with diverse ethnic and socioeco-
nomical backgrounds is infected.
Received April 9, 2020; accepted April 21, 2020. doi:10.1002/cpt.1864
1Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The 
Netherlands; 2Dutch Knowledge Center Pharmacotherapy for Children, The Hague, The Netherlands; 3Department of Paediatrics, Erasmus MC, Sophia 
Children’s Hospital, Rotterdam, The Netherlands; 4Royal Dutch Pharmacist Association, The Hague, The Netherlands; 5Certara UK Limited, Sheffield, 
UK; 6Intensive Care and Department of Paediatrics Surgery, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands. *Correspondence: 
Saskia N. de Wildt (Saskia.deWildt@radboudumc.nl)
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Chloroquine (CHQ) is proposed for coronavirus disease 
2019 (COVID-19) treatment. CHQ for malaria treatment in 
children is safe, but pediatric dose requirements for COVID-19 
are lacking.
WHAT QUESTION DID THIS STUDY ADDRESS?
 What is the best-evidence, model-informed CHQ dose to 
recommend when pediatric clinical trial data is absent?
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 Pediatric CHQ dose recommendations for COVID-19 were 
determined. Children 6 months to 12 years of age are in need of 
30% higher mg/kg doses, whereas younger children need 20% 
lower doses than older children and adults.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 A knowledge driven, model-informed approach can be used 
to support off-label dose recommendations, in the absence of 
clinical data, in case of a high medical need.
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Emerging data prompted the US Food and Drug 
Administration (FDA) to issue the emergency use authorization 
of chloroquine (CHQ) to treat COVID-19.2 The mechanism of 
action of CHQ for COVID-19 is not known, but it has been hy-
pothesized that CHQ acts through inhibition of endosome-me-
diated viral entry, and pH dependent steps in viral replication.3 In 
addition, reduced cytokine release by immune cells could possi-
bly benefit patients having a severe immune response.3 For adults, 
in vitro and modeling studies have explored the potentially effec-
tive plasma and tissue concentrations to treat COVID-19.4,5 The 
Dutch Centre for Infectious Disease Control (CIDC) recom-
mends a total cumulative dose of 3,300 mg CHQ base (44 mg/kg 
for a 75 kg adult), reducing the risk of adverse events by limiting 
treatment to 5 days.6 The Dutch Pediatric Formulary (DPF), the 
government supported, national source for pediatric drug infor-
mation and drug doses,7 set out to determine a best-evidence 
CHQ dose for children with COVID-19.
As CHQ is licensed for use in children with malaria,8 it may 
seem rational to use the World Health Organization (WHO) 
recommended antimalarial dose to treat COVID-19 infected pe-
diatric patients (25 mg/kg given over 3 days).9 However, applying 
these licensed doses may not be optimal to treat COVID-19. In fact, 
the current pediatric WHO dose may even be questionable for the 
treatment of malaria, as recent studies show that older infants and 
children may need a higher mg/kg dose to reach similar drug con-
centrations as adults.10–12 In contrast, it is likely that neonates and 
young infants will need lower doses per kg body weight. CHQ is 
metabolized by the drug metabolizing enzymes CYP3A4 (~ 15%) 
and CYP2C8 (~ 20%) and is renally excreted (~ 56%, leaving ~ 9% 
unknown additional clearance).4 All these processes are immature at 
birth and show an increase to adult values in the first years of life.13
Physiologically-based pharmacokinetic (PBPK) modeling com-
bines drug-specific properties and physiological properties to 
model drug disposition and drug action. Both the FDA as well as 
the European Medicine Agency support the use of these models to 
determine the optimal dose also for children.14–16
Hence, we aim to model and simulate CHQ exposure in chil-
dren and propose optimal dosing regimens for COVID-19.
METHODS
PBPK model building
Simcyp version 19 was used for simulations, which were performed 
using the predefined North European white “Sim-Healthy volunteer” 
and “Sim-Paediatric” populations. Default age-related physiological pa-
rameters (e.g., ontogeny in CYP3A4 expression, CYP2C8 expression, 
and renal clearance) were verified previously.17,18 Parameters in pediat-
ric subjects were redefined over time as explained by Abduljalil et al.19 
The CHQ compound file, built and verified by Yao et al. in adults, was 
derived from the Simcyp repository and used without modifications.4 
For all simulations, the proportion of female patients was set to 0.5.
PBPK model verification
To verify the model, plasma CHQ concentrations from Zhao et al. 
(American, healthy adults, African, malaria-infected children) and 
Karunajeewa et al. (Melanesian, malaria-infected children) were com-
pared with the simulated concentrations.10,20 Adults received a single 
300  mg CHQ base tablet, the children (6  months–12  years) ~  10  mg 
base/kg (cut) tablets q.d. for 3  days, respectively. Only minimum and 
maximum concentrations were extracted from the published figures 
using WebPlotDigitizer version 4.1, because individual values could not 
be identified from the plots.
Simulations were performed for at least 400 individuals per age group 
and trial size was based on the number of patients in the studies above. For 
adults, a single dose of 300 mg was simulated for 10 trials of 40 subjects 
(18–65 years).
For children, doses of 10  mg/kg q.d. for 3  days (30  mg/kg total) 
were simulated. For the 6-month to 5-year-olds, 4 trials of 123 subjects 
were simulated, and for the 5 to 12-year-olds, 6 trials of 76 subjects. 
Simulations were run for 7 days and clinically measured data were over-
laid with PBPK simulated concentration-time profiles to verify the 
CHQ PBPK model.
Dose selection in children
Simulations were performed using the standard body weight (75 kg) 
normalized adult oral dose of 44  mg base/kg, as proposed by the 
Dutch CIDC.6 A loading doses of 8  mg/kg is followed by 4  mg/kg 
after 12  hours. Maintenance doses on days 2–5 are given as 4  mg/
kg twice daily. Age groups were defined as 0–1 month, 1–6 months, 
6  months to 5  years, 5–12  years, and adults (18–65  years) based on 
the age groups defined in the Zhao et al. PK study (3 oldest cohorts), 
and expected age-related changes based on CYP and GFR maturation 
(2 youngest cohorts). Simulations were performed in 10 trials using 
40 subjects per trial and run over 70-day periods. The area under the 
curve (AUC) was calculated from 0 up until ~  5 reported half-lives 
(70  days) after the first dose, at which point virtually all drug is re-
moved from the system.8 AUCadult and AUCpediatric values were used 
to optimize dosing regimens by multiplying the AUC ratio with total 
adult dose (44 mg/kg) using this formula:
The loading doses tested were the licensed pediatric dose (10 mg/kg followed 
after 6  hours by 5  mg/kg) and the Dutch CIDC adult dose (8  mg/kg fol-
lowed after 12 hours by 4 mg/kg). The remainder of the total pediatric dose 
was equally divided over 8 doses administered twice daily on days 2–5. Revised 
doses were then re-entered into the simulator to confirm that they resulted in 
similar exposure (within a 5% limit) compared with the adult dose. We assume 
that matching systemic CHQ exposures in the different age groups results in a 
similar lung exposure, as predicted by Yao et al.
RESULTS
Model verification
PBPK model simulations were compared with observed values in 
adults and children 6  months to 12  years of age (Figure 1a–c). 
Mean plasma concentrations were predicted well, as our doses fell 
within the reported concentrations ranges. Around 160  hours 
after dosing, the model slightly overpredicted measured concen-
trations by Zhao et al. Observed variability seemed larger than 
predicted variability.
Dose selection in children
Simulations with the recommended adult dose (44 mg/kg) in all 
age groups resulted in AUC ratios (adult/pediatric age group) di-
verting from 1 and differing by age group (Table 1). Using these 
AUC ratios, new dosing regimens were calculated and simulated 
for the previously defined age groups (Figure 1d–h). The new 
age-adjusted doses, with corresponding AUC values are reported 
in Table 1. To simplify the dosing schedule for clinical use, the 
dose recommendations were rounded (Table 1).
(1)Total pediatric dose=
AUCadult
AUCpediatric
∗Total adult dose
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DISCUSSION
Our study presents age-adjusted CHQ doses for treatment of 
COVID-19 in children across the pediatric age range. These 
doses support previous pharmacokinetic (PK) studies in pediatric 
patients with malaria showing a need for higher mg/kg doses, as 
compared with adults, to reach similar plasma exposures in chil-
dren 6 months to 12 years.10–12 In addition, these doses account 
for immature drug metabolism and renal function, as reflected by 
Figure 1 Simulations of chloroquine (CHQ) pharmacokinetic (PK) profiles for model verification (a–c) and individual age-group adjusted CHQ 
PK predictions (d–h). Simulations of CHQ concentration-time profiles in a adults (300 mg, single dose) and b, c children 6 months to 12 years 
(10 mg/kg q.d. for 3 days). Solid lines indicate mean simulated values. Dotted lines indicate the first and 99th simulated percentile. Black 
vertical lines indicate the range between minimum and maximum values reported by Zhao et al.10 Grey vertical lines indicate the range 
between minimum and maximum values reported by Karunajeewa et al.20 Age adjusted doses: (d) Adult simulation. Dose on day 1: 8 mg/kg 
followed by 4 mg/kg after 12 hours. Dose on days 2–5: 4 mg/kg twice daily. (e) Pediatric simulation in children 5–12 years of age. Dose on 
day 1: 10 mg/kg followed by 5 mg/kg after 12 hours. Dose on days 2–5: 5.4 mg/kg twice daily. (f) Pediatric simulation in children 6 months 
to 5 years of age. Dose on day 1: 10 mg/kg followed by 5 mg/kg after 12 hours. Dose on days 2–5: 5.2 mg/kg twice daily. (g) Pediatric 
simulation in children 1–6 months of age. Dose on day 1: 10 mg/kg followed by 5 mg/kg after 12 hours. Dose on days 2–5: 3.7 mg/kg twice 
daily. (h) Pediatric simulation in children 0–1 month of age. Dose on day 1: 10 mg/kg followed by 5 mg/kg after 12 hours. Dose on days 2–5: 
2.5 mg/kg twice daily. Panels in the right upper corner indicate simulations in the first week of treatment.
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the need of lower doses in children < 6 months of age, compared 
with older children.13
We verified our model by comparing simulated and observed 
concentrations from published PK studies in adults and children. 
Mean concentration-time profiles seemed to reasonably reflect 
the observed CHQ concentrations.10,20 The simulated variability 
tended to be smaller than that observed in children. This may be 
explained by rounding of the dose in the original studies, as the 
oral tablet formulation did not allow precise weight-based dos-
ing. In one study, tablets were cut into quarters and halves, in the 
other study, two strength tablets were used.10,20 As simulations 
were in the same range as the published data and generally cap-
tured central tendency of these data, the model is considered ad-
equate for the purpose of pediatric dose extrapolation based on 
exposure-matching.
As the dosing schedule proposes higher mg/kg doses than the 
currently licensed pediatric dose for malaria treatment, safety ques-
tions may arise. Especially as lethal toxicity in children has been 
reported.21,22 The children in these toxicity reports received un-
intentional overdoses of ~ 35–100 mg/kg CHQ (base) in a single 
dose.21 These doses are much higher than proposed here. In studies 
in children > 6 months with malaria, doses of 50 and 70 mg/kg 
(in a 3-day schedule) were well-tolerated, with no severe cardiac 
adverse event.11,23 For the youngest age groups, exposure matching 
should result in similar concentrations as in older children. From 
literature search and consultancy with malaria experts, no special 
safety issues for neonates emerged, only after significant overdoses. 
In general, children with QT prolongation had very low mortal-
ity.24 Nevertheless, we recommend daily monitoring of potential 
adverse events, including corrected QT interval prolongation by 
echocardiogram monitoring, before treatment and daily afterward.
Our study has several other limitations and assumptions. We 
used a dosing schedule aiming for similar plasma exposures as with 
the adult dose proposed by the Dutch CIDC.6 This is a pragmatic 
combination of the registered malaria dose and the prolonged treat-
ment suggested by the recent COVID-19 studies, avoiding higher 
than adult exposures. If currently ongoing studies show more opti-
mal dosing regimens in adults for COVID-19, we will reconsider 
pediatric doses using the same concept of exposure-matching in-
formed by PBPK modeling.
In addition, the plasma target for COVID-19 is not clearly 
established. The reported in vitro antiviral half-maximal ef-
fective concentrations of CHQ (half-maximal effective con-
centration = 5.47 μM ref. 4 and 1.13 μM ref. 5) will not be 
reached in plasma by the current proposed dose (factor 2–10 
too low). Considering the extremely large volume of distribu-
tion of CHQ (100–200 L/kg20), up to 400 times higher con-
centrations may be reached in lung tissue, providing adequate 
antiviral exposure, as simulated by Yao et al.4 In this study, 
we assume that matching systemic exposure in adults would 
result in similar lung concentration of CHQ in pediatrics, 
which requires further investigation.
Another limitation of our model is the lack of PK data to ver-
ify the pediatric CHQ simulations of children < 6 months of age. 
The SIMCYP pediatric model has been extensively verified for 
CYP3A, CYP2C8, and renally cleared drugs in this age range.17,18 
Moreover, the CHQ dose predictions are in line with our under-
standing of maturation of these processes.13 Regarding absorption, 
the compound file developed by Yao et al. uses a first-order ab-
sorption model developed using adult data only.4 As absorption in 
adults is almost complete, we do not expect a major effect of this 
limitation on the plasma concentrations in children.
Table 1 Age-adjusted pediatric dose recommendation
Age group
AUC ratio  
(AUCadult/ AUCpediatric)
New age adjusted dose 
(mg/kg)
AUC after new age 
adjusted dose (SEM) 
mg/L.hour Final age-adjusted dose advice (mg/kg)
Adults and 
children 
> 12 years
NA 44 (day 1: 8 mg/kg, 
followed by 4 mg/kg after 
12 hours. Days 2–5: 
4 mg/kg twice daily).
76.6 (1.1) 44 mg/kga (day 1: 8 mg/kg, followed by 
4 mg/kg after 12 hours. Days 2–5: 4 mg/kg 
twice daily; max dose: 3,300 mg).
Pediatric 
5–12 years
1.33 58.5 (day 1: 10 mg/
kg, followed by 5 mg/kg 
after 12 hours. Days 2–5: 
5.4 mg/kg twice daily).
76.4 (0.8) 55 mg/kg (day 1: 10 mg/kg, followed by 
5 mg/kg after 12 hours. Days 2–5: 5 mg/kg 
twice daily; max dose: 3,300 mg).
Pediatric 
6 months to 
5 years
1.29 56.8 (day 1: 10 mg/
kg, followed by 5 mg/kg 
after 12 hours. Days 2–5: 
5.2 mg/kg twice daily).
76.1 (0.8) 55 mg/kg (day 1: 10 mg/kg, followed by 
5 mg/kg after 12 hours. Days 2–5: 5 mg/kg 
twice daily).
Pediatric 
1–6 months
1.01 44.4 (day 1: 10 mg/
kg, followed by 5 mg/kg 
after 12 hours. Days 2–5: 
3.7 mg/kg twice daily).
76.9 (0.8) 47 mg/kg (day 1: 10 mg/kg, followed by 
5 mg/kg after 12 hours. Days 2–5: 4 mg/kg 
twice daily).
Pediatric 
0–1 month
0.80 35.2 (day 1: 10 mg/
kg, followed by 5 mg/kg 
after 12 hours. Days 2–5: 
2.5 mg/kg twice daily).
77.3 (1.1) 35 mg/kg (day 1: 10 mg/kg, followed by 
5 mg/kg after 12 hours. Days 2–5: 2.5 mg/kg 
twice daily).
AUC, area under the curve; NA, not applicable.
aAdults receive a dose for an average (75 kg) individual irrespective of body weight (44 mg/kg × 75 kg = 3,300 mg total dose).
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If efficacy for treatment of COVID-19 is to be evaluated in 
children, it is important that the right dose will be used, leading 
to comparable exposures as in adults. As the expected number of 
COVID-19 pediatric patients in need of CHQ treatment will be 
small, randomized trials to evaluate efficacy are less feasible in this 
population. Collecting sparse PK data, especially in neonates and 
infants under CHQ treatment for COVID-19, for whom currently 
no data are available, allows further verification and improvement 
of the PBPK model. In addition, although ethically challenging, 
data on tissue distribution will be extremely valuable to confirm 
predictive performance of future models.
In conclusion, we present best-evidence CHQ doses for pediat-
ric COVID-19. We recommend the use of these doses to provide 
children optimal exposure with the highest chance of efficacy and 
safety. The knowledge-driven, model-informed dose selection par-
adigm presented in this study can serve as a science-based alterna-
tive for the DPF to recommend pediatric dosing when pediatric 
clinical trial data is absent.
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